Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates
have shown anti-angiogenic properties on tumor vasculature.
This study is meant to test the therapeutic potential of an anti-angiogenic treatment
strategy by combining all these agents for metastatic breast cancer patients.